Full Report

Know the Business

Tenet is two very different businesses bolted together: a low-margin chain of 50 acute-care hospitals and a high-margin national platform of 533 ambulatory surgery centers (USPI). The hospital segment is a regulated, labor-heavy utility earning ~10–11% operating margins; USPI is a physician-joint-venture compounder earning ~34–37% margins. Consolidated multiples mask this — about half of recurring operating income comes from the segment that generates one quarter of revenue, and the market is still pricing the company as a single hospital company.

1. How This Business Actually Works

Tenet sells the same thing twice — a surgical procedure — through two very different channels. In the hospital, a knee replacement is reimbursed at inpatient rates (high gross dollars, but heavy fixed cost in nurses, beds, EMTALA obligations and self-pay leakage). In a USPI ambulatory surgery center, the same case is reimbursed at lower gross dollars but with no ER, no overnight stay, no charity-care obligation, and physicians who own equity and bring their book of cases. The dollars per case fall; the margin per case roughly triples.

USPI is 24% of revenue but contributed roughly half of FY2025 segment operating income. Crucially, the next layer down rewrites the picture again. USPI is a portfolio of physician joint ventures: of $1.78B Ambulatory operating income, $805M was distributed to noncontrolling interests (the doctors and health-system partners), so Tenet's economic share is closer to $970M. In the Hospital segment, NCI takes only $155M of $1.73B. After NCI, Tenet keeps roughly 57% from hospitals and 43% from USPI — but USPI's piece grows 6–8% organically while the hospital piece is essentially flat in volume.

The FY2024 spike is not operating: $2.92B of it was a one-time gain on the sale of 14 hospitals to Catholic Health Initiatives, UCI Health and others. Strip it out and FY2024 normalized op margin was ~13.5%. The shape of the business is the steady upward grind from 2020 to 2025 once the divestitures and pandemic noise are removed — that grind is USPI's mix shift, not the hospitals.

2. The Playing Field

Tenet sits in a strange spot in the peer set: smaller and more levered than HCA, more profitable than UHS or CYH, and meaningfully more ambulatory-mix than any of them.

What the comparison reveals: HCA is the structural winner — it operates at twice Tenet's hospital scale, has superior payer leverage, and converts cleanly to cash; the market rewards that with the highest P/E. Pure hospital peers (UHS, CYH) trade at 7x earnings or worse because the market treats acute-care as a regulated commodity with cyclical labor cost risk. Encompass (post-acute rehab) and Surgery Partners (ASC pure-play) trade richer because their economics resemble Tenet's USPI more than its hospitals. Tenet's blended P/E of 12.8x sits between these worlds because the consolidated income statement combines them; the implicit question is whether Tenet should converge upward toward EHC/SGRY or downward toward UHS/CYH.

What "good" looks like in this set is a combination of (a) ambulatory mix above 25% of EBITDA, (b) net leverage below 3x, and (c) commercial managed-care share above 65% of net patient service revenue. Tenet now meets all three (USPI is ~50% of EBITDA, leverage 2.83x ex-NCI, managed care 70% of hospital revenue). Two years ago it met none.

3. Is This Business Cyclical?

Hospital operators are not cyclical in the GDP sense — Americans get sick on a schedule that ignores the business cycle — but they are intensely policy-cyclical and labor-cyclical, and those cycles dominate everything else.

Three cycle vectors actually move the needle:

Reimbursement / policy cycle. This is the dominant one. The Affordable Care Act expanded Medicaid in 2014 and lifted hospital admissions; the COVID emergency funding lifted 2020–2021; the One Big Beautiful Bill Act (OBBBA, July 2025) and the late-2025 expiration of enhanced premium tax credits are now running the other way. Management already flags that exchange revenues — about 6% of consolidated revenue — fell ~10% in Q1 FY2026, with most of the headwind expected through 2027. The OBBBA's Medicaid work requirements, supplemental-payment caps and tighter eligibility checks take effect in 2027 and Tenet has flagged it cannot yet quantify the impact.

Labor cycle. 2022 was the recent textbook: contract nurse rates spiked, salaries-wages-benefits absorbed 200+ basis points of margin, and Tenet's operating margin compressed from 13.5% to 10.9% in a year despite revenue holding flat. By 2025 SWB had fallen back to 40.8% of revenue. California's new healthcare-worker minimum wage (October 2024 onward) and the 20% unionization rate in hospital ops are the standing risks.

Volume / acuity cycle. Smaller and more nuanced. Q1 FY2026 saw a 41% drop in respiratory admissions (a mild flu season) trim hospital admissions growth by 90bps. Outpatient migration is a structural multi-decade trend, not a cycle — and it favors Tenet because USPI captures it.

USPI itself is far less cyclical: ASC volumes are tied to elective procedures (orthopedics, ophthalmology, GI), commercial pricing rises annually, and ASCs do not carry charity-care or ER obligations. The 2022 labor shock barely touched USPI margins. The right framing is that hospitals carry the cycle exposure; USPI doesn't.

4. The Metrics That Actually Matter

Forget gross margin and revenue growth — they conflate the segments. The five metrics below are what determine whether Tenet creates or destroys value in any given year.

The metric most analysts get wrong is the last one. Headline EBITDA looks healthy, but ~$960M flowed to USPI's physician partners in 2025 before Tenet ever saw it — about 24% of consolidated EBITDA. Free cash flow after NCI is the true cash flow to Tenet shareholders, and management's 2026 guide of $1.6–$1.83B (after a $150M one-off Conifer tax payment) implies a ~$1.87B run-rate. That is the number that funds buybacks and debt paydown, not the consolidated $4B EBITDA figure.

The metric most management teams over-emphasize is utilization of licensed beds (49.8% in Q4 FY2025). It barely moves and barely matters at this level — what matters is mix within those beds (commercial vs. Medicaid vs. uninsured) and acuity per case.

5. What Is This Business Worth?

Value here is determined by two separable engines, not one. Treating Tenet as a single hospital operator at a blended P/E ignores that USPI deserves an ASC-platform multiple while the hospitals deserve a commodity-acute-care multiple. Sum-of-the-parts is the right lens.

Binder Error: Set operations can only apply to expressions with the same number of result columns

What the SOTP teaches: at the low end the market is roughly fair on Tenet — you are paying for a struggling acute-care utility plus a USPI stake at trough multiples. At the high end there is meaningful upside because USPI alone, valued like the only listed pure-play (Surgery Partners, which Bain offered to take private at ~12x EBITDA in 2024), accounts for the majority of the market cap before you assign anything to the hospitals. The decisive question is not the precise multiple — it is whether you believe USPI's economics deserve to be looked at separately at all.

The wrong way to value this is a single P/E or EV/EBITDA. The blended 7.85x EV/EBITDA looks cheap until you remember (a) ~24% of EBITDA leaves the door as NCI distributions; (b) the hospital half deserves something closer to 5–6x; and (c) leverage of $10B net debt amplifies any error in either direction. The right way is two engines, two multiples, one debt stack, one cash pile.

6. What I'd Tell a Young Analyst

Stop treating Tenet as a hospital company. It is now an ASC platform with a hospital ballast. Build USPI on its own line — same-facility revenue growth, net revenue per case, EBITDA, NCI distributions, M&A spend — and judge it against Surgery Partners and Optum's SCA Health, not against HCA.

The single most important number is free cash flow after NCI, not EBITDA. A 24% leakage to USPI's physician partners is structural and growing — every USPI acquisition adds revenue on Tenet's income statement and a partner check below it. Anyone modeling consolidated EBITDA without subtracting NCI is double-counting.

Underwrite three risks honestly and stop arguing about the rest. (1) The OBBBA hits in 2027 and Tenet has not quantified it; states will implement work requirements and provider-tax caps differently and four of Tenet's eight hospital states have not expanded Medicaid. (2) Premium tax credits expired end of 2025 — about half the headwind is in Q1 numbers, and the second half is coming. (3) California seismic compliance for hospitals by 2030 is an unquantified capex liability that management has refused to size. Everything else (denials, nurse wages, cyber) is noise around these.

What the market may be underestimating: the Conifer ownership consolidation (Tenet returns to 100% from 76.2% effective January 2026, with $1.9B of payments from CommonSpirit over three years) is a clean cash-flow positive event that has been buried under the OBBBA narrative. The buyback ($1.39B in 2025, another $318M in Q1 2026, $1.49B remaining authorization) compounds the ownership story for patient holders — share count is down 15% in four years.

What would change the thesis: a USPI acquisition of size from a strategic, a Tenet decision to spin USPI public, or — bearishly — a single state (Texas or Florida) implementing OBBBA Medicaid changes more aggressively than peers. Watch state-level supplemental-payment program approvals quarterly; that is the leading indicator.

The Numbers

Tenet Healthcare has spent the last seven years quietly converting from a leveraged, low-margin hospital operator into a deleveraged, ambulatory-led cash machine — operating margin has tripled from roughly 5% in FY2017 to 15% in FY2025, free cash flow has gone from negative-to-flat to $2.5B, and net debt is down by a third. The market has paid for it: the stock is up roughly 6x since 2020. The single number most likely to re-rate or de-rate the shares from here is EV/EBITDA on a clean, post-divestiture EBITDA base: at 6.4x today the shares trade about one turn below the 16-year mean of 8.3x, which is what investors get paid to underwrite continued execution against a slow-growth, regulation-heavy hospital backdrop.

The Quality Score is a 0–100 composite of profitability, balance-sheet health, predictability and cash-conversion strength derived from the financials shown below. Fair Value is the base-case triangulation from EV/EBITDA mean reversion and is detailed in the closing section.

Price as of 2026-05-01. Tenet operates 50 acute-care hospitals plus a controlling interest in USPI, the country's largest network of ambulatory surgery centers (≈518 ASCs as of year-end 2024). After divesting nine hospitals across South Carolina, California and Alabama in 2024, the mix has tilted decisively toward higher-margin ambulatory work.

Quality Scorecard

The scorecard combines fundamentals-based health checks readers care about — distress risk (Altman Z), accounting durability (Piotroski F), capital efficiency (ROIC, ROE), and earnings volatility. Scoring is computed from current filings.

The picture is a mid-quality compounder rather than a fortress: profitability and cash conversion are now genuinely strong, but Altman Z still sits in the grey zone because of intangible-heavy assets and a long history of episodic write-downs. Predictability is the soft spot — earnings have been distorted by impairments (2017), the pandemic (2020–21), and divestiture gains (2024), making clean comparables hard.

Revenue and Earnings Power — 16-Year View

Revenue jumped on the 2013 Vanguard Health acquisition and again on the 2015 USPI roll-up, then plateaued near $18–21B as the company sold underperforming hospitals. The margin story is the more important one: operating margin doubled from the mid-single-digits of 2013–17 to a structural 11–15% range from 2021 onwards, driven by mix shift toward ambulatory, contract renegotiations with payers, and 30+ hospital divestitures. FY2024's 27.6% operating margin is not the new run-rate — it includes a $2.916B pre-tax gain on hospital divestitures; the underlying margin was closer to 13–14%.

Quarterly Direction

Revenue is remarkably steady at $5.0–5.5B per quarter — the divestitures stripped capacity but pricing/mix offset most of it. The operating-margin spike in 1Q24 (60%) is the single $2.9B divestiture gain landing in one quarter. The underlying quarterly margin run-rate is 13–17%, with 1Q26 starting the year at 23% — a strong setup heading into the May earnings print.

Cash Generation — Are the Earnings Real?

Cash conversion is the story behind the rerate. Trailing five-year FCF / Net Income runs 129% ($8.5B FCF on $9.5B net income), with FCF exceeding net income in seven of the last ten years. FY2024 looks like an inversion only because reported NI included a non-cash $2.9B divestiture gain; on a clean basis, OCF still tracks above adjusted NI. Capex has crept higher (now $1.0B vs $0.7B average) reflecting investment in ASC build-outs, but FCF is still hitting record levels.

Capital Allocation

The capital allocation playbook flipped between 2022 and 2025. Acquisitions averaged over $1B / year in 2020–21 (USPI minority buy-in), then collapsed; buybacks took over, scaling from zero to $1.39B in 2025 — the largest in the company's history. Net debt repayment has been a constant $2–3B / year drumbeat, funded partly by re-issuance at lower coupons. There is no dividend.

Balance Sheet Health

Net debt has come down only modestly ($14.5B → $10.3B over 7 years) — the deleveraging story is really about the denominator. EBITDA more than doubled, dropping ND/EBITDA from a balance-sheet-stretched 8x in 2015 to a comfortable 2.5x today. FY2024's 1.6x reading is again the divestiture distortion. This single trajectory explains most of the equity rerate: hospital operators with ND/EBITDA above 5x trade as "stressed credit"; below 3x they trade like consumer-defensives.

Stock Price — The Rerate

The shares went from $14 in March 2020 to over $200 by mid-2025 — a 14-bagger driven almost entirely by EBITDA expansion and multiple normalization, not multiple expansion alone. The pull-back from $203 to $183 over the past two quarters is part profit-taking, part recognition that the divestiture EBITDA tailwind is largely complete.

Valuation — Now vs Its Own 16-Year History

This is the chart that answers the only question that matters for new money: is the rerate done, or is there more to come?

At 6.4x EBITDA, the shares trade roughly one full turn below the 16-year mean but in line with the 5-year average. The market is asking for proof that FY2024's adjusted EBITDA base ($3.6B clean of the divestiture gain) compounds, rather than reverts. If EBITDA stays around $4B and the multiple drifts back to its 16-year norm, the math points to the high-$200s. If the market loses confidence and the multiple falls to the 5.5x trough seen post-2017, the stock has roughly $122 of fundamental support — about 33% downside from here.

Per-Share Economics

Three things stand out: (1) EPS turned reliably positive only in 2020, (2) book value per share crossed zero in the same year after a decade of negative book from aggressive buybacks at low prices, and (3) FCF per share has roughly tripled to $27.85 since 2018 — that's the engine of the rerate. The company has retired 14% of shares since 2022.

Peer Comparison — FY2025

Tenet now leads the peer set on FCF margin (11.9%) — ahead of even HCA (10.2%) — with a cleaner balance sheet (2.5x ND/EBITDA) than stretched HCA (4.5x) or stressed CYH (6.5x). HCA still scores higher on operating margin and absolute scale and trades at a quality premium; CYH is the value trap; EHC is the smaller, higher-multiple compounder. THC sits as the "good-quality, fair-price" mid-cap option. ROE is left blank for HCA and CYH because equity is negative — both have run buybacks far enough to wipe out book equity.

Fair Value Range

What the Numbers Say

The numbers confirm that Tenet has executed a real, durable margin transformation: operating margin tripled, FCF turned consistently positive at over a billion dollars a year, ND/EBITDA went from distressed to investment-grade-adjacent, and per-share book value finally turned positive after a decade underwater. They contradict the headline narrative that 2024 was a structural step-change — a third of FY2024 operating income was a one-shot divestiture gain, and the FY2025 numbers (with operating margin re-normalizing to 15% and EBITDA back near $4.1B) are the real apples-to-apples comparison. Watch in the next four quarters: (1) whether ASC same-store growth at USPI stays in the high single digits, (2) whether the buyback pace ($1.4B in 2025) sustains into 2026 absent further divestitures, and (3) the May 2026 Q1 print — consensus is $4.42 EPS and the company already reported $8.01, so the next step is whether the run-rate margin in Hospital Operations holds above 13%.

Where We Disagree With the Market

The market is debating the wrong unit. Both the sell-side ($217 mean target, three big cuts on May 1) and Stan's bull/bear frame argue over an EV/EBITDA multiple — but at THC, 41% of consolidated net income leaves the door as USPI noncontrolling-interest distributions before any shareholder sees a dollar, and a ~$540M one-time CommonSpirit cash payment plus a $1.36B non-interest-bearing CHI note are flattering 2026 cash flow. Strip those out and the per-share-FCF compounder thesis that anchors most "buy" notes is mechanically broken in FY26 — for the first time since 2022, organic FCF-after-NCI is guided flat-to-down, and the buyback math that "compounds independent of any rerate" depends on the cash that the guide says will not be there. We also believe the Fuzzy Panda compliance tail is meaningfully underpriced because the SEC's own FOIA Exemption 7(A) refusal is a concrete signal of an active enforcement matter — a fact the market is treating as "no Wells notice = no risk." Our resolution path is dated and observable: Q2 FY26 cash bridge (Jul 22), Q3 FY26 OBBBA framing (early Nov), and the FY27 initial guide on the Q4 FY26 call (Feb 2027).

Variant Perception Scorecard

A 70 on variant strength reflects a real, materially monetizable disagreement (per-share cash mechanics distorted by the Conifer unwind, NCI leakage, and an underpriced compliance tail), but not an exotic one — sell-side targets have started moving toward us already, with three major banks cutting on May 1, 2026. Consensus clarity is high because the cuts, the ISS QualityScore, the Lone Pine / Wellington / Eminence Q4 buyer set, and the Trefis "Capital Compounder" framing are all observable. Evidence strength is high because most of our claims are deterministic — the FY26 Adj. FCF less NCI guide of $1.6–1.83B versus FY25's $1.84B actual is in the press release; the $540M CommonSpirit one-time is in the Q1 10-Q; the SEC's FOIA Exemption 7(A) refusal is on file. The decisive resolution event is the FY27 initial guide on the Q4 FY26 call (≈Feb 2027), so this is a 9-month horizon trade, not a multi-year one.

Consensus Map

The Disagreement Ledger

Disagreement #1 — Per-share FCF compounder is broken in FY26 once Conifer unwind is stripped. A consensus analyst would say Tenet retired ~$1.4B of stock in FY25 against $1.84B FCF less NCI — call it 75% payout — and a 7% buyback yield speaks for itself. Our evidence pushes back: FY26 guide for Adj. FCF less NCI is $1.6–$1.83B, BELOW FY25 actual, and Q1 OCF was supported by $540M of one-time CommonSpirit cash. If we are right, the bull's "buyback compounds at 9%/year independent of rerate" stops compounding at the FY26 step — either the pace slows or the funding shifts to debt drawdown, killing the deleveraging story. The cleanest disconfirming signal is two consecutive quarterly prints (Q2, Q3) where Adj. FCF less NCI annualizes inside the guided range AND a fresh buyback authorization is announced before $1.17B exhausts.

Disagreement #2 — Compliance tail is mispriced because the SEC's own FOIA Exemption 7(A) refusal is a real signal. Consensus reads "no Wells notice yet" as "no risk." Our evidence pushes back: Exemption 7(A) is specifically reserved for documents that would interfere with an active enforcement proceeding. Tenet/NME has paid >$2.5B in fines over 20 years in the exact coding/outlier categories the new short report alleges, and the 2003 outlier scheme was first surfaced in analyst reports before the SEC filed civil fraud charges in 2007 — a precedent pattern. If we are right, a $675–$845M reserve (3–4% of market cap) belongs in any clean DCF/SOTP, and the next 10-Q's Item 3 language is the binary. The cleanest disconfirming signal is the FY2026 10-K closing without any new disclosure plus a specific, detailed company rebuttal on the earnings call referencing hospital-level cost-report data.

Disagreement #3 — Bull and bear are fighting the wrong segment. A consensus analyst would tell you USPI's same-facility revenue trajectory in Q2 and Q3 is the decisive read. Our evidence pushes back: USPI is a bounded growth band already largely embedded in the current multiple; the real binary that swings fair value from $122 to $244 is the Hospital segment's response to OBBBA Medicaid across the four hospital states (TX, FL, AZ, MI) that have not expanded Medicaid. If we are right, the institutional move is to re-orient the watch list to hospital adjusted-admission revenue (already -1.5% Q1) and state-agency rule postings, not USPI. The cleanest disconfirming signal is two consecutive prints where hospital adj-admission revenue prints non-negative AND Texas or Florida publish OBBBA implementation rules at the gentler end of the framework.

Evidence That Changes the Odds

How This Gets Resolved

What Would Make Us Wrong

The first place we are most exposed is the per-share-FCF disagreement. Tenet has beaten every annual EBITDA, USPI EBITDA, and FCF guide since FY24 by ~$500M and the FY26 guide is conservative by design — management explicitly said they did not raise after a 23.2% margin Q1. If FY26 Adj. FCF less NCI exits the year above the high end of the guide and a fresh buyback authorization is announced before $1.17B exhausts, our claim that "the cash that funds the compounder is going down" looks too clever — the right read becomes "guide buffer," not "broken mechanic." The strongest counter-evidence already exists: Q1 FY26 Adj. FCF was $978M with the buyback running at $318M, and management has earned credibility on cash. We would need to see two clean quarters where the run-rate falls inside $1.6–$1.8B even excluding Conifer cash to keep this disagreement.

The second place we are exposed is on Fuzzy Panda. FOIA Exemption 7(A) refusals are routine when an SEC matter is open at any stage — including matters that close without action. The 18–24 month enforcement timeline means a clean 10-K through Feb 2027 is a real possibility, in which case the tail premium evaporates and we are paying for protection that did not need to be priced. The 2007 SEC outlier action took four years from inquiry to settlement; the 2025 short report is less than 12 months old. Time is on the bull's side here, not ours.

The third place we are exposed is on the segment reorientation. If the Senate clears 60 votes on the House-passed EPTC extension before November ACA open enrollment, the hospital binary partially defuses, USPI's bounded growth band still earns a reasonable multiple, and the entire variant collapses back into "the consensus is roughly right at $217." That outcome is genuinely possible — the House passed the extension 230–196 with 17 Republicans voting yes, and OBBBA has bipartisan critics in red states with rural hospital exposure.

A useful red-team summary: the bull's "$244 mean reversion" math could be exactly right if (a) the Senate passes EPTC, (b) Q2/Q3 USPI revenue holds at 6%+, (c) FY26 Adj. FCF less NCI exits at the top of the guided range, and (d) a fresh buyback authorization lands before $1.17B exhausts. Three of those four are inside management's control. Our variant view is not that this is impossible — it is that the cumulative probability of all four is meaningfully lower than what a $217 mean PT implies, because the cash and FOIA pieces are independent of management's playbook.

The first thing to watch is the Q2 FY26 cash-flow bridge on July 22, 2026 — specifically whether organic Adj. FCF less NCI (excluding any further CommonSpirit unwind cash) prints inside the FY26 guided range without a buyback step-down.

Bull and Bear

Verdict: Watchlist — the structural bull case (USPI as an ASC platform inside a hospital chassis) is real, but the deterministic data has already turned against it for the next 12 months. FY26 EBITDA growth guides to +1.5% versus +14% in FY25, FY26 Adjusted FCF less NCI is guided below FY25 actual, and USPI same-facility case volume printed −2.1% in FY25 — the very metric the bull's platform multiple depends on. Management has also explicitly stated it "cannot yet quantify" the 2027 OBBBA Medicaid hit, leaving the back-half of the thesis window open-ended. The bull's $244 mean-reversion math and the 9%/year buyback are intact, so this is not a short — but waiting for either (a) two clean prints of USPI same-facility case volume turning positive, or (b) management putting a number on OBBBA, costs little versus stepping in front of a cycle that has visibly turned.

Bull Case

Bull's price target: $244/share (+33% from $183.27) on 12–18 months. Method: EV/EBITDA mean reversion — 7.5x (halfway from current 6.4x toward the 16-yr mean of 8.3x) on FY26E Adj. EBITDA of $4.2B, triangulated against a SOTP midpoint of ~$20B equity. Disconfirming signal: USPI same-facility revenue growth under 4% for two consecutive quarters, OR a Wells notice / DOJ subpoena referencing the Fuzzy Panda outlier-payment allegations.

Bear Case

Bear's downside target: $122/share (−33% from $183.27) on 12–18 months. Method: 5.5x EV/EBITDA on $3.8B post-policy EBITDA (FY25 $4.566B less ~$250M EPTC less ~$500M base-case OBBBA Medicaid drag) — stressed-hospital trough multiples and the FY17 crisis-era floor on Tenet's own 16-yr history, cross-checked against UHS at 7.2x P/E and CYH peer comps. Cover signal: A 10-K Item 3 disclosure clearing the Fuzzy Panda allegations cleanly plus management quantifying OBBBA at sub-$200M annual EBITDA and reaffirming a $4.5B+ FY27 EBITDA guide.

The Real Debate

Verdict

Verdict: Watchlist. The bear carries more weight today because the bear's evidence is deterministic and already in the printed numbers — FY26 EBITDA growth has collapsed to +1.5%, FY26 FCF less NCI is guided below FY25 actual, USPI same-facility case volume is already negative, and management itself refuses to size the 2027 OBBBA hit. The single most important tension is the second one: USPI's same-facility case volume of −2.1% directly undermines the bull's right to ASC-platform multiples, because a platform that loses units cannot be valued on take-out comps drawn from growing platforms. The bull could still be right — the buyback retires shares at 9%/year independent of any rerate, the SOTP gap is real, and management has earned credibility by beating every guide since FY24 — so this is a watchlist setup, not a short. The verdict flips to Lean Long if either (a) USPI same-facility case volume prints non-negative for two consecutive quarters in 2H FY26, or (b) management quantifies OBBBA at sub-$200M annual EBITDA and reaffirms a $4.5B+ FY27 EBITDA guide. Until one of those lands, the cost of waiting is small relative to stepping in front of a cycle whose downside management has not yet sized.

Catalysts - What Can Move the Stock

Catalyst Setup

The next six months hinge on whether USPI's same-facility revenue growth holds at 6%+ across the Q2 (late July) and Q3 (early November) prints while the Senate decides the fate of the ACA enhanced premium tax credit extension that the House passed 230-196 on January 8, 2026. With Q1 already reported and the FY2025 10-K filed, the calendar in front of investors is moderate — three hard-dated events, two policy pivots with soft windows, and a steady buyback drip — but the stock is sitting 26% below its March 2026 high of $244 with three sell-side targets cut on the May 1 print, so any single catalyst that confirms or denies "USPI compounder vs. policy-impaired hospital" carries unusual leverage. The decisive question is no longer EBITDA growth — Q1 already showed the model can absorb the $250M EPTC hit — but whether the market re-segments USPI on ASC platform multiples or hardens the hospital-peer discount.

Ranked Catalyst Timeline

The rank deliberately puts Q2 earnings ahead of the EPTC vote even though the policy outcome carries higher economic magnitude. Q2 is dated (~July 22), bilateral (the bear thesis loses if USPI prints ≥6% with hospital margin holding) and proximate. The Senate vote is higher-magnitude but undated. Annual Meeting is hard-dated but low-impact unless say-on-pay unexpectedly cracks given the comp escalation. The Fuzzy Panda watchpoint sits at #7 not because it lacks magnitude — $675-845M is 3-4% of market cap — but because the resolution path itself is binary and undateable.

Impact Matrix

The matrix collapses to a simple read: the bull thesis lives or dies on USPI metrics in Q2 and Q3; the bear thesis lives or dies on the Senate EPTC vote and the state OBBBA rule postings. Buyback execution is the mechanical force that compounds whichever direction the policy + ASC verdict goes. The Fuzzy Panda question is a separate, asymmetric tail-risk leg that resolves on legal disclosure, not on operating performance.

Next 90 Days

The 90-day window (May 4 - Aug 2, 2026) is moderately busy: one governance vote, one earnings print, and a conference circuit, with two soft windows (Senate EPTC and Fuzzy Panda resolution) running underneath.

What Would Change the View

Three observable signals over the next six months would force the debate to update. First, the USPI same-facility revenue line in Q2 (July) and Q3 (November) — two consecutive prints ≥6% would push sell-side to model USPI as a separable ASC platform and reopen the path to the $244-358 SOTP range; two prints below 5% (especially with case volume still negative after FY25's -2.1%) confirm the bear's "growth is acuity-mix only" critique and reset consensus EBITDA. Second, the Senate vote on the House-passed ACA EPTC extension — extension reverses the quantified $250M FY26 headwind and undermines Goldman's standing policy-risk thesis; failure or floor-stall hardens the FY27 stack and makes the bear's $122 floor referenceable. Third, any 8-K, Wells notice, or 10-Q Item 3 language that references Medicare outlier payments or DRG coding — the Fuzzy Panda allegations sit at $675-845M (3-4% of market cap), and either a clean disclosure trail through the FY2026 10-K or a forced disclosure on enforcement would resolve a binary tail. State-level OBBBA implementation rules in Texas and Florida arriving aggressively in 2H 2026 would sit alongside these as the bear's preferred trigger for the FY27 setup, but rules typically lag rule-making notices by months — the leading indicator is the agency posting cadence, not a single dated event.

The Full Story

Between FY2021 and Q1 FY2026, Tenet went from a debt-laden 60-hospital operator with a stalled Conifer spin-off to a 50-hospital, ambulatory-led platform with leverage near 2.2x and a $1.5B buyback running. Management's narrative compressed in parallel — from "we are still transforming" to "we are a USPI-led compounder" to, most recently, "we are managing a real ACA-subsidy headwind without changing the model." The track record is unusually clean: every annual EBITDA guide since FY2024 has been raised mid-year and beaten at year-end, and the strategic priority stack has not moved in six consecutive earnings calls. The first overt headwind — a quantified $250M EBITDA hit from ACA premium-tax-credit expiration — has now arrived, and Q1 FY2026 shows the model can absorb it. Credibility is high; the new test is whether 2026's reaffirmation holds through OBBB Medicaid implementation in 2027.

1. The Narrative Arc

The shape of the story is unusually linear for a five-year window. There is no walk-back. The hospital-count drop is not a defensive shrink — it is a deliberate re-mix paired with USPI buildout (399 ASCs in 2021 → 533 in 2025). Net debt fell roughly $2.5B even while Tenet repurchased ~22% of shares.

The flat 2021–2023 stretch hid the real work — divestiture proceeds offsetting growth — before the inflection in 2024 once the SC and Alabama sales closed and USPI margin expansion compounded. The FY26 guide implies +1.5% growth at the midpoint, which is materially below the underlying 10% normalized rate management has framed (the gap is the $250M ACA-exchange headwind).

2. What Management Emphasized — and Then Stopped Emphasizing

The diagonals tell the story: deleveraging fades as it succeeds; buyback rises in its place; ambulatory and high-acuity language hardens into the permanent identity; COVID and pre-COVID comparisons drop out entirely once the model can stand on its own; AI and ACA-policy language enter late and now dominate the forward narrative. Conifer is the most interesting line — quietly de-emphasized for three years, then central to a single quarter (Q4 FY25, when the JV exit was announced), then receding again as a wholly-owned in-house function.

3. Risk Evolution

The risk discussion has been re-aimed almost entirely from operational shocks (pandemic, contract labor) toward policy and technology shocks (ACA expiration, OBBB Medicaid, AI, cybersecurity). Three threads matter most:

• ACA enhanced premium tax credits expired Dec 31, 2025 — telegraphed in the FY24 risk factors, quantified at $250M of FY26 EBITDA in the Q4 FY25 call. AZ, MI and CA carry disproportionate exchange exposure.
• OBBB Medicaid — work requirements, state-directed payment caps, provider-tax limits. Tenet says it cannot quantify, but most provisions take effect in 2027. Management has begun "structural" cost work explicitly for that horizon.
• Cybersecurity moved from generic to concrete in FY2022 after a real ~$100M-impact incident. Notably, the Change Healthcare cyberattack is never named in Tenet's risk factors despite affecting the entire industry.

4. How They Handled Bad News

The data set has very little clear "bad news." There is no missed quarter, no rescue refinancing, no scandal, no covenant scare. The two negative events that did show up were handled in the same way — early disclosure, quantified impact, narrative absorbed into the existing model:

• Cybersecurity incident (April 2022, ~$100M pre-tax): disclosed promptly, recovered within the year. Not used as an excuse on subsequent calls.
• ACA subsidy expiration (Q4 FY25): management opened with the headwind, sized it ($250M EBITDA), explained the regional concentration, and reaffirmed the model. Q1 FY26 then beat internally and management refused to raise — a deliberate choice to hold credibility through the year.

What is more telling is the absence of pattern: management never blamed weather, payer mix, or contract labor as a one-time excuse. Q1 FY26 delivered an in-line quarter despite a 41% drop in respiratory admissions and active weather disruption; the call presented this as evidence the model is robust, not as a reason to reset.

"We are not altering our business strategy because of healthcare policy uncertainty." — Sutaria, Q1 FY25

This line, delivered before the subsidy expiration was confirmed, is the cleanest read on management posture. They did adjust cost structure for the policy environment (AmbientScribe pilots, autonomous coding, Conifer analytics productivity doubling) — but the strategic story did not move.

5. Guidance Track Record

The two completed annual cycles (FY24, FY25) each ran ~$0.5B above the initial midpoint. The pattern is consistent: conservative initial guide, mid-year raise, beat the raised range. The one outright miss is the 2022-vintage 575–600 ASC target for end-2025 — Tenet finished at 533, ~50 short. Management never repeated the explicit ASC count target after FY2023, replacing it with a dollar-deployed framework ($250M annual baseline; $350M deployed in 2025). This is a quietly-dropped commitment, not a denied one.

Why 8.5: every quantified annual EBITDA, USPI EBITDA, and FCF guide since FY2024 has been beaten — most by wide margins. Capital allocation framework has been articulated and executed (deleverage → buyback → USPI M&A — in that priority order). The single dropped commitment (ASC count target) is benign. Marks against a 10: hospital admissions were softened mid-year in FY25; the 2026 guide implicitly relies on a -20% exchange-enrollment assumption that is unverifiable today; the company has not yet been tested by a true earnings disappointment in this management's tenure.

6. What the Story Is Now

Tenet today is described — and trades — as a USPI-led ambulatory compounder with a streamlined high-acuity hospital portfolio attached. The current story has three pillars:

1. USPI is the durable growth engine. 533 ASCs and 26 surgical hospitals; ~40% segment EBITDA margins; orthopedics framed as a 5–10-year growth runway; inpatient-only list phase-out as a regulatory tailwind; $250M baseline annual M&A pace with Q1 FY26 already at $125M.
2. The hospital footprint is "right-sized" and operationally improved. 50 hospitals, high-acuity case mix, 17.5% peak segment margin in Q1 FY25, contract labor "in line with historical levels." Westover Hills (San Antonio, 2024) and Florida Coast (Port St. Lucie, 2025) signal selective new builds in chosen high-growth markets.
3. Capital allocation is shareholder-friendly and disciplined. ~22% of shares retired since 2022, $1.5B authorization active, leverage near 2.2x, no significant debt maturities until late 2027.

What to believe: the operational discipline. Six consecutive quarters of double-digit EBITDA growth despite hospital divestitures, then an in-line Q1 FY26 absorbing weather, respiratory weakness, and exchange erosion simultaneously. What to discount: the "valuation is disjointed" framing in management buyback commentary — after a $244 stock price in March 2026, that line lands very differently than it did at the Q1 FY25 print.

The story is now simpler than at any point in the prior decade. Whether it stays simple depends entirely on the OBBB Medicaid trajectory through 2027–2028.

The Forensic Verdict

The reported numbers are not faithful representation of recurring economic reality without adjustment, but the distortion is openly disclosed rather than hidden. FY2024 net income of $4.064B contained $2.916B of pre-tax ($2.143B after-tax) gains from hospital divestitures booked inside GAAP operating income — which inflated the FY2024 operating margin to 27.6% versus a 13.4% underlying rate. Cash flow does not lie: 3-year aggregate CFO/Net Income is 1.03x and FCF/Net Income is 0.68x, working-capital does not flatter cash, and DSO actually improved from 52 days (FY2023) to 44 days (FY2025). The two structural concerns that hold this away from a "Watch" grade are (i) a 20-year compliance rap sheet topped by a $900M False Claims Act settlement and a five-year Corporate Integrity Agreement that expired before the most recent reporting period, and (ii) a June 2025 short report from Fuzzy Panda Research alleging fresh Medicare outlier-payment gaming and upcoding, with estimated potential fines of $675M-$845M. The single data point that would most change the grade is a clean disposition of those allegations, either by an explicit company rebuttal with hospital-level cost-report data or by the next 10-K confirming no government inquiry.

Grade: Elevated. Underlying earnings quality is acceptable, but the company's reporting demands aggressive de-noising and the regulatory tail is real. An institutional investor should underwrite the headline numbers at a discount to GAAP operating income, treat FY2024 EPS as a non-comparable base, and reserve a possibility-weighted reserve for outlier-payment claw-back exposure.

Shenanigans Scorecard

Breeding Ground

The structural setup is not founder-controlled or governance-thin, but it has two real amplifiers: incentive design that rewards adjusted metrics over GAAP, and a 20-year history of False Claims Act settlements concentrated in the same coding/outlier areas the new short report alleges. Compensation governance is otherwise reasonable — Say-on-Pay passed at 93% in 2025, the audit committee is independent, Deloitte has rendered unqualified opinions, and there is no record of late filings or material-weakness restatements.

The compensation structure deserves a careful read. The Adjusted EBITDA definition strips out both "net gains (losses) on sales" and "impairment and restructuring charges and acquisition-related costs," so the FY2024 divestitures did not directly inflate management's bonus payout. However, the bar — Adjusted EBITDA of $3,995M in FY2024, $4,566M in FY2025 — sits on a smaller asset base after the divestitures. Margin expansion is partly mix-shift toward USPI ambulatory centers, which carry higher economic margins but also more noncontrolling-interest leakage. Hot-checking the bonus math is worth doing every cycle.

Earnings Quality

The FY2024 income statement is unusable as a like-for-like base. Underneath the divestiture-gain noise, the underlying earnings track is healthier — but the headline cannot be left unadjusted in any model.

The $2.916B FY2024 gain on sale (booked above the operating-income line under "net gains on sales, consolidation and deconsolidation of facilities") is the single biggest earnings-quality call in the file. The FY2024 EPS of $32.70 is overstated by approximately $21.89 per share by the company's own reconciliation. Adjusted FY2024 EPS is roughly $10.81, against $15.49 in FY2025 — that is the actual growth comparison.

Roughly 41% of FY2025 consolidated net income — $960M — flowed to USPI minority partners. Investors who anchor on consolidated net income overstate Tenet's share of earnings by 1.7x. This is structural to the USPI joint-venture model, not a shenanigan, but it makes Adjusted EPS and Adjusted FCF Less NCI the right anchor metrics rather than consolidated cash flow or net income.

Receivables actually fell 13% in FY2024 because the divested hospitals carried their AR off the balance sheet at sale; the FY2025 comparison normalizes. There is no Sherman-style buildup of working capital that would suggest channel-stuffing or aggressive booking. Combined with the DSO improvement to 44 days, this is a genuine earnings-quality positive.

Cash Flow Quality

Underlying cash conversion looks good once the FY2024 tax distortion is taken out, but the volatility year over year is high enough that single-year FCF is a misleading anchor.

The FY2024 inversion — net income of $4.064B but CFO of only $2.047B — is the largest gap in eight years and is fully explained by the $2.916B non-cash gain plus $1.028B higher cash tax payments. FY2025 reversed: CFO $3.540B against NI of $2.367B as the cash taxes normalized and operating efficiency improved. The 3-year aggregate (FY2023-FY2025) tells the truth: $7.96B CFO against $7.74B NI = 1.03x conversion, and $5.27B FCF = 0.68x conversion. Those are reasonable for a hospital + ambulatory-surgery operator.

Acquisition-adjusted FCF is the most useful single number for an acquisitive consolidator. By that measure, FY2025's $2.22B is genuinely strong, FY2024's $0.55B was depressed by both elevated taxes and acquisition cadence, and FY2021's negative $0.31B is a reminder that the USPI buyout cycle can swallow reported FCF. Nothing here suggests CFO is being mechanically inflated through receivable sales, supplier finance, or accelerated collections; the MD&A explicitly attributes FY2024 weakness to "income tax payments that were $1.028 billion higher" and FY2025 strength to "the timing of other working capital items." Both are credible mechanical explanations.

Metric Hygiene

Tenet runs three non-GAAP measures: Adjusted EBITDA, Adjusted EPS, and Adjusted Free Cash Flow (with the variant "Free Cash Flow less NCI"). The reconciliations are clean, included in proxy and 10-K, and have not changed definitions in the last three years. The hygiene risk is not redefinition — it is the gap between non-GAAP and GAAP and the fact that Adjusted EBITDA grew through years of GAAP volatility.

Goodwill rose by $890M from FY2023 to FY2025 even as Tenet divested 14 hospitals. The build is concentrated in USPI: at year-end 2024, $7,994M of $10,691M goodwill (75%) sits in the Ambulatory Care segment versus $2,697M in Hospital Operations. Tenet purchased controlling interests in 54 ASCs and one surgical hospital during FY2024 and another 27+1 in FY2025. Each purchase creates goodwill at acquisition and adds noncontrolling interest on the balance sheet. The qualitative goodwill impairment test passed at October 2024; that test will be the most important single forensic disclosure if USPI growth slows or rates compress.

What to Underwrite Next

The five items that should drive the next quarterly read are concrete and named.

First, monitor the 10-K language around the Fuzzy Panda allegations. A material government inquiry into outlier payments would be required disclosure under Item 3 (Legal Proceedings) and as a subsequent event. The absence of any specific reference in the FY2025 10-K — combined with confirmation that Item 9A internal controls remain effective — would be the single biggest signal that the short thesis is not landing.

Second, track the Adjusted FCF Less NCI figure quarter by quarter and reconcile it to consolidated CFO. The compensation committee uses this measure for both AIP and LTI. The risk is not redefinition; it is whether the noncontrolling-interest distribution number on the cash flow statement equals or exceeds the noncontrolling-interest income on the income statement. If NI to NCI ($960M FY2025) keeps running ahead of cash distributions to NCI for multiple years, joint-venture working capital is silently financing the parent — exactly the kind of disclosure gap to monitor.

Third, watch USPI same-facility revenue and case-volume disclosures. ASC same-facility revenue grew 6.8% in Q1 2025 with a 12% bump in joint replacements; FY2025 case volume was -2.1%. Mix-shift toward higher-acuity (and higher-margin) cases is the official explanation, but if management starts excluding categories from the same-facility cut, that is a metric-hygiene downgrade signal.

Fourth, check whether goodwill keeps building faster than acquisition cash outflows. FY2024 saw $571M of acquisition cash but goodwill rose $384M; FY2025 saw $308M of acquisition cash and goodwill rose $507M. The reconciliation is opaque without the M&A footnote — purchase-price allocation choices, contingent consideration, and step-up of previously held equity interests can all create goodwill without matching cash. A widening cash-to-goodwill gap is a yellow flag for an acquisitive compounder.

Fifth, monitor effective tax rate. FY2025 dropped to 15.5% versus FY2024's 22.6% and a historical 20-25%; the 10-K cites "utilization of interest expense carryforwards due to gains from sales of facilities" as a 2024 item. A repeat low-teens effective rate without comparable gains is a sustainability question for FCF projections.

The signal that would downgrade this work to "Watch" (sub-30): an explicit, detailed company response to the Fuzzy Panda allegations with hospital-level cost-report data, plus a clean FY2025 10-K with no new legal disclosure and continued double-digit organic Adjusted EBITDA growth. The signal that would upgrade this to "High" (60+): any of (i) a Wells notice, formal SEC inquiry, or DOJ subpoena referencing outlier payments or DRG coding; (ii) a material weakness in internal controls; (iii) an unexpected goodwill impairment in either segment; (iv) a redefinition of Adjusted EBITDA or Adjusted FCF Less NCI to expand the addback list.

Bottom line for position sizing. This forensic profile is not a thesis breaker, but it is a position-sizing limiter and a valuation haircut. Underwrite Tenet on Adjusted EBITDA and Adjusted FCF Less NCI rather than GAAP earnings, treat FY2024 as a non-recurring base, and reserve roughly 3-5% of market cap for a possibility-weighted government-claims tail. The compliance history and the live short-seller report mean a long position should carry a wider margin of safety than the underlying cash-conversion picture would otherwise suggest.

The People

Governance grade: B–. Tenet has a credibly independent board, a shareholder-friendly capital return record, and a pay-for-performance plan that actually paid out at maximum because results beat targets. But the same year saw the CEO collect $43M, the Board sign a fresh long-tenure employment agreement plus a special retention LTI grant, NEOs receive $11M of off-plan cash retention bonuses, and almost every named officer and several directors sell stock — with zero open-market buys. Combined Chairman/CEO and an aging Lead Director cap the upside.

1. The People Running This Company

Five executives matter. The CEO is a former McKinsey senior healthcare partner promoted up from inside; the rest of the team was mostly built around him in 2023–2025. Notable: the COO role was created in May 2025, the CFO joined as an NEO only in 2024, and four of the five received special cash retention bonuses in May 2025 — meaning the bench is still being locked down.

Sutaria is the case here. He came from McKinsey, joined Tenet as COO in 2019, became CEO in September 2021, then assumed the Chairman role in August 2023 — an unusual three-year escalation. The amended employment agreement signed January 23, 2025 runs through end-2028 with auto-extensions, raised target bonus from 150% to 200% of base, and added a separately-granted retention LTI award not reflected in the standard target grant value table. He is competent and credible — Tenet's transformation around USPI, deleveraging, and divestitures happened on his watch — but Tenet has effectively front-loaded retention payments to keep him from leaving.

The accounting officer, Ramsey, having zeroed out his ownership twice within twelve months while still in role, is a small but real yellow flag.

2. What They Get Paid

CEO total compensation jumped 75% year-over-year, from $24.7M to $43.1M, the bulk of it from a $31.7M stock-award line that includes a one-time retention LTI grant tied to the new employment agreement. The board did this in the same year that 2023 long-term performance awards vested at 225% of target (the maximum possible) and 2025 annual bonuses paid at 200% of target. Pay was earned on the metrics — but the metrics were also reset upward in 2025.

The 2023 LTI awards vested in February 2026 at the maximum 225% of target: every annual tranche cleared the maximum threshold (Adj EPS $6.98/$11.88/$16.78; Adj FCF less NCI $1.18B/$0.59B/$1.84B), and Tenet placed first in three-year TSR against Community Health, HCA, and UHS, triggering the +25% multiplier. So the pay was earned. The concern is structural: the relative-TSR peer group is only three companies, with ranking-1 worth +25% and ranking-4 only -25% — a narrow, asymmetric benchmark that is easy to game with capital returns.

Pay ratio: 711-to-1. Median employee comp was $60,657; Sutaria $43.1M. Even adjusted out of the special retention LTI, the ratio remains in the 400s.

3. Are They Aligned?

This is the section that drives the verdict.

Ownership

Tenet has no founder, no promoter, no controlling holder. Insider ownership of all 16 officers and directors is 0.95% of shares outstanding (less than 1%). The shareholder register is dominated by passive index complexes.

Sutaria's 533,564 shares are worth roughly $127M at recent prices — meaningful in absolute dollars, but built almost entirely from compensation grants rather than purchases. The other officers each hold less than $10M.

Insider buying vs selling

There were no open-market insider purchases in the trailing twelve months. There were many open-market sales.

The single largest move: Sutaria sold 78,762 shares on September 10, 2025 for ~$15.0M at $190–192. The Form 4 contained no reference to a 10b5-1 plan. Three weeks earlier Foo sold $1.4M; in the same quarter every active NEO trimmed exposure post-RSU vest. After the February 2026 RSU vests, Arnst sold 32,000 shares for $7.5M, Arbour sold 6,500 for $1.5M, Ramsey sold the remainder of his entire stake for $1.9M.

This is the strongest negative governance signal in the file. Insiders are net sellers across every level of the org chart while paying themselves at maximum on every compensation lever.

Dilution and capital allocation

The capital-return record is the strongest positive offsetting the insider-selling concern:

Tenet repurchased $1.4B of stock in 2025 (8.8M shares) — well in excess of dilution from RSU vests and grants. The buyback is sized credibly relative to the $1.84B of adjusted FCF less NCI; it reduces share count net of insider liquidations. No dividend is paid; capital returns are 100% buyback.

Related-party behavior

The proxy discloses no related-party transactions of consequence between Tenet and its officers or directors. Director Agarwala's a16z fund invests in healthcare technology that could create conflicts; the proxy notes none rose to the disclosure threshold. No officer or director has pledged any shares of common stock — a clean positive.

Skin-in-the-game score

A 4/10. Sutaria has real dollar exposure ($127M of stock) and is on an employment agreement through 2028 with retention equity, so he is locked in. But the ownership came from compensation, not personal investment, and the trailing twelve months of insider flow is uniformly outbound. Other executives hold trivial amounts net of tax-withholding sales and have just been paid $11M of cash retention bonuses to stay, suggesting management thinks the optimal way to keep its team is contractually rather than through equity alignment. The capital-return record (and the absence of pledges) is what keeps this from being lower.

4. Board Quality

Twelve directors. Eleven independent. The CEO is the only insider. The board is functionally diversified across healthcare operating, regulatory/policy, finance/audit, and military/risk experience — but it is also old: four directors are 73 or older, including the Lead Director.

The committee chairs are credible: Romo chairs Audit (former Southwest CFO; experienced public-company audit chair via Ryder), Kerrey chairs HR (long Senate / governor career, plus Allen & Co), FitzGerald chairs Nominating/Governance (Columbia, multiple healthcare boards), Bierman chairs Quality, Compliance & Ethics (former Owens & Minor CEO/CFO). All four had committee experience before joining their current chair roles.

The structural weaknesses:

The Audit Committee report and the absence of any disclosed material weakness, restatement, or reportable governance lapse are positives. The board met its 75% attendance standard for every director in 2025.

5. The Verdict

Grade: B–.

The strongest positives. Eleven of twelve directors are genuinely independent, with deep individual credentials. The pay plan paid for performance: 2023 LTI vested at the maximum 225% of target only because adjusted EPS, FCF, and three-year TSR cleared every threshold. $1.4B was returned to shareholders via buyback in 2025 — a ratio that reduces share count net of all insider grants and sales. No pledged shares. No related-party transactions. No founder or controlling holder; one share, one vote.

The real concerns. CEO and Chairman are the same person, and the independent Lead Director who would otherwise check that combination is 82 and chairs the committee that sets his pay. The 2025 CEO package of $43M was 75% larger than 2024, partly because the board signed a fresh 2025–2028 employment agreement with a separate retention LTI grant on top of the regular plan; in the same year, four NEOs received $11M of cash retention bonuses outside the regular plan. While all of that was happening, the CEO sold $15M of stock in a single September transaction with no 10b5-1 disclosure, and every other named officer was a net seller. Pay-for-performance is real, but the levers are narrow: the relative-TSR benchmark is only three peers, and 2023 awards vested at the cap on every dimension.

The single thing most likely to upgrade. Splitting the Chair and CEO roles, or rotating in a younger Lead Director with no role on HR Comp, would move this to a clean B+ very quickly.

The single thing most likely to downgrade. Another quarter of heavy open-market insider selling — particularly any unscheduled CEO sale — combined with any quality-of-care or compliance event that surfaces in the QCE Committee disclosures, would push this to C+.

Web Research — Tenet Healthcare (THC)

The Bottom Line from the Web

The web tells a more conflicted story than Tenet's filings do alone. Two facts the financials don't show: a June 2025 short-seller report from Fuzzy Panda Research alleging ~$168M of excess Medicare outlier payments, with FOIA records hinting at unreleased SEC documents — and a wave of insider selling worth ~$26M+ in the eight months through March 2026, including the CEO's $15M open-market sale. Meanwhile sell-side targets are sliding fast: Wells Fargo cut its target from $265 to $213 on May 1, 2026, Guggenheim from $283 to $252, and Morgan Stanley from $260 to $254 — all in one day, after a Q1 2026 print where revenue ($5.37B) missed estimates and same-store sales went flat. Underneath that, the CommonSpirit/Conifer transaction is materially reshaping 2026 GAAP earnings with ~$1.65B of one-time termination revenue.

What Matters Most

Web-discovered Headline Metrics

Recent News Timeline

What the Specialists Asked

Insider Spotlight

Saumya Sutaria, M.D. — Chairman & CEO. Joined Tenet Jan 2019 as COO; CEO Sep 2021; Chairman Aug 2023. Pre-Tenet: 18 years at McKinsey & Company in healthcare and PE practices. UC San Diego M.D. with UCSF post-grad training. 2025 total comp $43.1M (vs $24.7M in 2024 / $18.5M in 2023). Beneficial ownership: 592,073 shares post Feb 2026 RSU vesting. Sold $15M (78,762 shares) on Sept 10, 2025 with no 10b5-1 plan disclosed.

Sun Park — EVP & CFO. 2025 total comp $7.37M ($700K salary, $2M bonus, $2.7M stock, $1.75M incentive). Held 31,629 shares post Feb 2026 RSU vesting. CFO sales appear to be tax-withholding events around RSU vests, not open-market sales — distinguishing his profile from peers.

Tom Arnst — EVP, Chief Admin Officer & GC. 2025 total comp $10.05M (notably $4M bonus). Sold a combined 32,000 shares for $7.5M in early March 2026 at $234–$239, near the year's highs.

Lone Pine Capital, Wellington, and Eminence Capital are the high-conviction Q4 2025 bulls. Lone Pine added 1.79M shares ($355M) — its first material stake. Wellington added 1.04M shares (+1,114%). Eminence took a new $225M position. Counter-positioned: Citadel cut 1.02M shares (-96.7%) and UBS AM cut 693K (-75.8%).

Industry Context

Hospital sector — for-profit operator dynamics. HCA Healthcare beat profit and revenue but kept its annual forecast unchanged, sending shares down nearly 5% — signaling that even sector leaders are facing reset expectations. The whole for-profit hospital cohort is contending with: (1) lower exchange enrollment after ARPA subsidy expiration, (2) Medicaid supplemental payment normalization, and (3) a continued shift from inpatient to outpatient settings.

OBBBA (One Big Beautiful Bill Act) is the policy tail risk. Tenet's own 10-Q calls out the OBBBA as a 2027+ pressure factor on Medicare and Medicaid economics. Goldman Sachs cited "increasing concerns about policy risks" in its Dec 2024 downgrade — those concerns have not gone away.

Outpatient migration is the structural tailwind. Tenet's 559 ASCs put it ahead of HCA on outpatient mix; the Q1 2026 USPI segment EBITDA growth of +6.1% on 10.6% revenue growth shows where the operating leverage actually lives in the business. Ambulatory acquisitions in 2025: 27 ASCs + 1 surgical hospital. Industry consolidation continues to favor scale players.

Liquidity & Technicals

A meaningful position is feasible at THC's current trading profile, but block size and participation discipline still matter. The technical setup is bearish on the 3–6 month horizon — price has rolled below the 200-day SMA and the post-June-2025 uptrend has cracked, with momentum confirming the loss of leadership.

Portfolio implementation verdict

Price snapshot

The stock has more than 50% of its 52-week range to give back, sitting almost exactly mid-range despite a 50% gain over the trailing year — the move was front-loaded into mid-2025 and has rolled over since.

Trend regime — full price history with 50/200 SMAs

Price is below the 200-day SMA ($183.27 vs $196.51, a 6.7% gap). The 50-day at $207 sits between price and the recent high, capping any rebound. After a once-in-a-decade rally from $15 in late-2016 to $244 in early-2026, THC is now in a clear corrective phase — the long-term uptrend remains intact on the SMA structure (50 still above 200) but the price has lost both moving averages and is testing whether the broader trend is salvageable or whether a fresh death cross is forming.

Relative strength vs benchmark

The relative-performance feed shipped without SPY or XLV series populated, so a clean rebased benchmark comparison is not available in this run. The company series alone is shown below, rebased to 100 at t=−756 trading days (~3 years); over the same window the broad market posted roughly 35–45% gains, so THC is dramatically outperforming on level even after the recent drawdown.

THC remains a multi-bagger over three years even after the recent drawdown — the rebase index sits at 266 vs the 100 base. The shape is what matters: the index made a peak near 311 in late-2025 and has rolled to 266 over five months. That deceleration is the relative-strength tell — leadership is fading even though absolute levels still dwarf the broader market.

Momentum — RSI and MACD

RSI(14) sits at 42.6 — neutral with a bearish lean, well off the overbought 70+ readings that accompanied the late-2025 rally and recovering off a sub-30 oversold reading from late April. MACD histogram is negative (line at −6.36, signal at −6.08) but the histogram has compressed from −0.68 back to −0.28 in three sessions. This is a momentum bottom forming, not yet a momentum reversal — confirmation requires a histogram cross above zero and an RSI close above 50.

Volume, volatility, and sponsorship

The three highest-conviction volume events in the 10-year window were all distribution days — two of them more than 24% lower on the session. Recent 12-month volume has tracked the 50-day baseline closely with one notable cluster in late-February 2026 around the rally peak; there has been no panic-volume capitulation in the current corrective phase, which is why the tape still has potential downside to clear before a base forms.

Realized 30-day volatility sits at 35.3% — comfortably in the "normal" regime (above the 31.8% calm-band p20 floor, below the 62.8% stressed-band p80 ceiling). The market is not yet pricing a stress event. The vol risk is asymmetric: a break of $172 likely re-prices vol toward the 50-percentile of 43.6% and widens the trading range materially.

Institutional liquidity panel

ADV runs at $292M against a $16.65B market cap — a 1.76% daily turnover ratio and a 345% annualized turnover. By any institutional yardstick this is a deeply liquid name, and the 20-day ADV is meaningfully above the 60-day ($292M vs $260M), suggesting recent re-rating events have pulled in marginal participation rather than driving it away.

Fund-capacity table

Liquidation runway

Median 60-day daily range is 1.49% of price — under the 2% red-line where impact costs become punitive. Block trades up to ~1.5M shares clear within a single session at a 20% participation cap, and a 1% issuer-level stake exits inside three trading days at the same cap.

The largest position that clears within five trading days at 20% ADV participation is roughly 1.0% of market cap (a 0.5% stake at the more conservative 10% ADV cap). A multi-strategy fund up to $5.7B can run a 5% portfolio weight under aggressive participation; under a 10% ADV constraint, that supportable AUM falls to $2.9B.

Technical scorecard and stance

Stance: bearish on the 3–6 month horizon. THC has lost the uptrend it built through mid-2025, momentum is bottoming but has not yet reversed, and there is no volume signature of either capitulation or accumulation. The clean invalidation levels: above $207 (reclaim of the 50-day SMA) flips the structure back constructive and re-opens $244; below $172 (Bollinger lower at $175.66, ATR-2σ stop, prior consolidation support) confirms the downtrend and likely re-prices realized vol toward the 43.6% median, with $150 as the next visible target.

Liquidity is not the constraint. A fund of any reasonable size can act here without becoming the market — the right action is to wait, not to size into a deteriorating tape. Build only on a daily close above $207 with rising volume; trim or avoid into the current setup; cap initial sizing at 2% of NAV until the histogram crosses positive and RSI clears 50.